Loading organizations...
Enzymit: Biotech company designing novel enzymes with AI and cell-free biomanufacturing for bioproduction of complex molecules.
Enzymit is a Nes Ziona, Israel-based biotechnology company that utilizes artificial intelligence and computational protein design to develop novel enzymes for cell-free biomanufacturing. The organization's proprietary platform synthesizes complex molecules and materials without relying on living cells, enabling faster and more efficient commercial bio-production across the fine chemical, foodtech, and cosmetics sectors. Operating with a team of 21 to 50 employees, the company recently partnered with Cosun to scale the production of high-purity hyaluronic acid, targeting a $15 billion market that serves major cosmetic brands like L'Oréal and Estée Lauder. To support its ongoing research and development efforts, Enzymit has raised a total of $15 million in venture capital financing, which includes a $10 million Series A funding round led by Khosla Ventures and Grove Ventures. The enterprise was founded in 2020 by Gideon Lapidoth and Dror Baran.
Enzymit has raised $5.0M across 1 funding round.
Enzymit has raised $5.0M in total across 1 funding round.
Enzymit has raised $5.0M in total across 1 funding round.
Enzymit's investors include First Star Ventures, Sapir Venture Partners.
Enzymit has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 6, 2022 | $5.0M Seed | First Star Ventures | Sapir Venture Partners |